{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:31:36Z","timestamp":1789471896509,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017035","name":"Fondation ISREC","doi-asserted-by":"publisher","award":["P01-CA240239"],"award-info":[{"award-number":["P01-CA240239"]}],"id":[{"id":"10.13039\/501100017035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017035","name":"Fondation ISREC","doi-asserted-by":"publisher","award":["NVKP_16-1\\u20132016-0017"],"award-info":[{"award-number":["NVKP_16-1\\u20132016-0017"]}],"id":[{"id":"10.13039\/501100017035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017035","name":"Fondation ISREC","doi-asserted-by":"publisher","award":["R01-CA218579"],"award-info":[{"award-number":["R01-CA218579"]}],"id":[{"id":"10.13039\/501100017035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017035","name":"Fondation ISREC","doi-asserted-by":"publisher","award":["R01-CA206890"],"award-info":[{"award-number":["R01-CA206890"]}],"id":[{"id":"10.13039\/501100017035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001927","name":"Advanced Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis Egyetem","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K24HL150238"],"award-info":[{"award-number":["K24HL150238"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL137562"],"award-info":[{"award-number":["R01HL137562"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL130539"],"award-info":[{"award-number":["R01HL130539"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35-CA197743"],"award-info":[{"award-number":["R35-CA197743"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-CA224348"],"award-info":[{"award-number":["U01-CA224348"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA259253"],"award-info":[{"award-number":["R01-CA259253"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA208205 R01-NS118929"],"award-info":[{"award-number":["R01-CA208205 R01-NS118929"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejca.2021.12.024","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:14:23Z","timestamp":1642551263000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Renin\u2013angiotensin\u2013aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-5318","authenticated-orcid":false,"given":"Zsofia D.","family":"Drobni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9099-3007","authenticated-orcid":false,"given":"Thiago","family":"Quinaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Zlotoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Zubiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sama","family":"Supraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-3187","authenticated-orcid":false,"given":"Veronika","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pittet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-3548","authenticated-orcid":false,"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.12.024_bib1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.12.024_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.12.024_bib3","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2021.12.024_bib4","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1073\/pnas.1819889116","article-title":"Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy","volume":"116","author":"Chauhan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"410","key":"10.1016\/j.ejca.2021.12.024_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2021.12.024_bib6","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","article-title":"Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events","volume":"24","author":"Pinter","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.024_bib7","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.12.024_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2012.10.015","article-title":"Angiotensin II drives the production of tumor-promoting macrophages","volume":"38","author":"Cortez-Retamozo","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2021.12.024_bib9","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2021.12.024_bib10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.12.024_bib11","unstructured":"Hong TS. A randomized phase 2 study of losartan and nivolumab in combination with FOLFIRINOX and SBRT in localized pancreatic cancer. Identifier: NCT03563248. August 10, 2018 - December 31, 2025;https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03563248."},{"key":"10.1016\/j.ejca.2021.12.024_bib12","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejca.2021.12.024_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.024_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2021.12.024_bib15","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.21873\/anticanres.14980","article-title":"Impact of renin\u2013angiotensin system inhibitors on the efficacy of anti-PD-1\/PD-L1 antibodies in NSCLC patients","volume":"41","author":"Tozuka","year":"2021","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.024_bib16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clgc.2021.04.002","article-title":"Angiotensin blockade modulates the activity of PD1\/L1 inhibitors in metastatic urothelial carcinoma","volume":"19","author":"Jain","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2021.12.024_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2021.12.024_bib18","first-page":"1073","article-title":"The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor","volume":"7","author":"Yoshiji","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.024_bib19","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.024_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cllc.2016.07.008","article-title":"Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small-cell lung cancer","volume":"18","author":"Menter","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2021.12.024_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-017-2528-3","article-title":"Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and\/or bevacizumab","volume":"134","author":"Levin","year":"2017","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.ejca.2021.12.024_bib22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3892\/mco.2015.630","article-title":"Angiotensin II type-1 receptor blockers enhance\u00a0the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients","volume":"3","author":"Osumi","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.024_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/2050640617695698","article-title":"Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma","volume":"5","author":"Pinter","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.ejca.2021.12.024_bib24","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-17-0256","article-title":"Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.024_bib25","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.12.024_bib26","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.024_bib27","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.024_bib28","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejca.2021.12.024_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/d41573-020-00204-y","article-title":"Combinations take centre stage in PD1\/PDL1 inhibitor clinical trials","volume":"20","author":"Upadhaya","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2021.12.024_bib30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejca.2021.12.024_bib31","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-related adverse events: a case-based approach","volume":"9","author":"Connolly","year":"2019","journal-title":"Front Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921013058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921013058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:52:51Z","timestamp":1778568771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921013058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"alternative-id":["S0959804921013058"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin\u2013angiotensin\u2013aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}